Programs for men's and women's sexual wellness clinics.
Shockwave, PRP, and peptide-based programs — with the device sourcing, protocol design, and staff training to run them safely at volume.
Sexual wellness clinics blend urology, gynecology, and aesthetic workflows. DRS supports both men's and women's programs with ECSWT platforms, PRP kits, and peptide protocols vetted for licensed prescribers — plus the marketing-safe medical claims boundaries clinics need.
Common indications we support
- Erectile dysfunction (vascular, mixed)
- Peyronie's disease
- Female orgasmic and arousal disorders (adjunct)
- Genitourinary syndrome of menopause
- Libido and hormone-adjacent peptide therapy
- Post-childbirth pelvic-floor recovery adjunct
Devices, biologics & protocols for this specialty
Focused low-intensity shockwave devices with treatment templates for men's and women's programs.
See ECSWT devicesFDA-cleared PRP prep systems used for P-Shot, O-Shot, and adjunctive sexual wellness procedures.
PRP optionsPepEdHub protocols for libido, arousal, and metabolic peptides with contraindication screens.
Peptide protocolsROI and staffing model for a sexual-wellness ECSWT program.
Practice playbookPublications relevant to this specialty
Curated evidence from our Publications library that references Programs for men's and women's sexual wellness clinics.
- Therapeutic peptides · 2026 curationPeptide Therapeutics: The 2026 Evidence Base
Therapeutic peptides are short amino-acid sequences that mimic or modulate the body's own signaling molecules. As of 2026, more than 100 peptide drugs are approved globally and roughly 170 more are in active clinical development, spanning metabolic, oncologic, dermatologic, and regenerative indications.
Why it's relevant: Contraindication screens and prescriber-ready starting doses.
Read the publication - Metabolic peptides · Head-to-head dataGLP-1 & Next-Generation Metabolic Peptides
GLP-1 receptor agonists have moved from adjunct diabetes therapy to first-line treatment for obesity and cardiometabolic risk. The 2026 evidence base now includes head-to-head data across semaglutide, tirzepatide, and the emerging triple agonist retatrutide.
Why it's relevant: Where weight-loss and sexual wellness protocols overlap.
Read the publication - Energy-based devices · Orthopedic, urologic, cardiacExtracorporeal Shockwave Therapy (ECSWT)
Focused and radial extracorporeal shockwave therapy uses short, high-energy acoustic pulses to trigger mechanotransduction, neovascularization, and controlled inflammation. The 2026 literature indexes more than 1,100 randomized or comparative trials across orthopedic, urologic, and cardiovascular indications.
Why it's relevant: Focused low-intensity shockwave programs with treatment templates.
Read the publication - AI & clinical decision support · 2026 review seriesAI in Clinical Practice: Peptide Protocols & Decision Support
AI-assisted clinical decision support is the fastest-growing area of the DRS library. Peptide protocol generation, contraindication screening, and post-market safety monitoring now sit at the intersection of validated LLM tooling and traditional pharmacovigilance.
Why it's relevant: Libido and hormone-adjacent peptides with prescriber oversight.
Read the publication
Bring regenerative medicine into your practice.
Talk with our team about biologics, devices, or an AI-powered peptide protocol tailored to your patients.